AstraZeneca, Merck announce promising results for breast cancer in trial 3
Bharti Jayshankar December 13, 2024: AstraZeneca and Merck have announced long-term results from the OlympiA Phase 3 trial, showing that Lynparza (olaparib) significantly.
Drugs
Pharma